Xiahepublishing Domain Overview🔒 SSL Verified
Live Data Status: |News & Media
Welcome to the detailed analysis for xiahepublishing.com. This domain is officially recognized as Xia & He Publishing. According to their official web presence, their primary focus is: "Founded in 2011 and headquartered in Texas, USA, XIA & HE Publishing Inc. is providing a platform for researchers to communicate their achievements, record the latest findings, and promote research in biomedicine.".
Table of Contents
- Tech Stack
- React
- Link Profile
- Internal Pages: 98Outbound Links: 9
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$305
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- xiahepublishing.comAvailable
- xiahepublishing.netAvailable
- xiahepublishing.orgTaken
- xiahepublishing.ioTaken
- xiahepublishing.coTaken
- xiahepublishing.aiTaken
Official Contact & Profiles
Content Snippets from xiahepublishing.com
"Randomized controlled trials (RCTs) have been conducted to evaluate treatment efficacy for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis. This study aimed to compare the effectiveness and safety of 11 promising targets among adults with MASLD."
"PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, Scopus, and Embase were searched from inception to November 20, 2024. The primary outcomes were fibrosis improvement ≥1 stage without worsening of steatohepatitis and steatohepatitis resolution without worsening of fibrosis. Additional outcomes included reductions in liver fat content, liver enzymes, metabolic profiles, and selected safety outcomes. The surface under the cumulative ranking curve (SUCRA) was used to rank efficacy."
"Of 11,584 articles screened, 44 eligible RCTs (11,410 participants, 33 medications) were included. For fibrosis improvement, d-(R)-pioglitazone (SUCRA: 79.3) and fibroblast growth factor (FGF) 21 analogs (SUCRA: 71.9) ranked higher. For steatohepatitis resolution, glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonists (RAs) (SUCRA: 91.7) ranked higher. Co-agonists of GLP-1/GIP/GCG and GLP-1/GCG receptors ranked higher for relative and absolute changes in liver fat content, respectively. For liver enzymes and glucose improvement, the combination of a GLP-1 RA and an acetyl-coenzyme A carboxylase inhibitor ranked higher. GLP-1 RAs, peroxisome proliferator-activated RAs, and FGF21 analogs showed favorable effects on lipid profile improvement."
"Incretin-based co-agonists and FGF21 analogs showed favorable profiles across key endpoints, while d-(R)-pioglitazone and GLP-1/GIP dual RAs ranked higher for fibrosis improvement and steatohepatitis resolution, respectively. SUCRA rankings should be interpreted in conjunction with effect sizes, uncertainty, and available safety data."
Key Topics & Focus Areas for xiahepublishing.com:
Authority Metrics: Score 89/100
Global Reach of Xiahepublishing
Competitor Analysis for .COM Domains
By comparing xiahepublishing.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to xiahepublishing.com.
Frequently Asked Questions
Is xiahepublishing.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of xiahepublishing.com?
As of July 23, 2026, xiahepublishing.com holds an estimated domain authority score of 49/100 based on our VisitRank tracking algorithms.
What are the top alternatives to xiahepublishing.com?
You can find the best alternatives and similar sites to xiahepublishing.com in our explore section, which includes competitors in the News & Media sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for xiahepublishing.com:
xaihepublishing.comxihepublishing.comxiiahepublishing.comxoahepublishing.comxiehepublishing.comxiahapublishing.comxiahepoblishing.comxiahepubloshing.comxiahepublishong.comxuahepublishing.com